TY  - JOUR
AU  - Petković, Aleksa
AU  - Erceg, Sanja
AU  - Munjas, Jelena
AU  - Ninić, Ana
AU  - Vladimirov, Sandra
AU  - Davidović, Aleksandar
AU  - Vukmirović, Luka
AU  - Milanov, Marko
AU  - Cvijanović, Dane
AU  - Mitić, Tijana
AU  - Sopić, Miron
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4955
AB  - Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.
PB  - MDPI
T2  - Cells
T1  - LncRNAs as Regulators of Atherosclerotic Plaque Stability
VL  - 12
IS  - 14
DO  - 10.3390/cells12141832
ER  - 

@article{
author = "Petković, Aleksa and Erceg, Sanja and Munjas, Jelena and Ninić, Ana and Vladimirov, Sandra and Davidović, Aleksandar and Vukmirović, Luka and Milanov, Marko and Cvijanović, Dane and Mitić, Tijana and Sopić, Miron",
year = "2023",
abstract = "Current clinical data show that, despite constant efforts to develop novel therapies and clinical approaches, atherosclerotic cardiovascular diseases (ASCVD) are still one of the leading causes of death worldwide. Advanced and unstable atherosclerotic plaques most often trigger acute coronary events that can lead to fatal outcomes. However, despite the fact that different plaque phenotypes may require different treatments, current approaches to prognosis, diagnosis, and classification of acute coronary syndrome do not consider the diversity of plaque phenotypes. Long non-coding RNAs (lncRNAs) represent an important class of molecules that are implicated in epigenetic control of numerous cellular processes. Here we review the latest knowledge about lncRNAs’ influence on plaque development and stability through regulation of immune response, lipid metabolism, extracellular matrix remodelling, endothelial cell function, and vascular smooth muscle function, with special emphasis on pro-atherogenic and anti-atherogenic lncRNA functions. In addition, we present current challenges in the research of lncRNAs’ role in atherosclerosis and translation of the findings from animal models to humans. Finally, we present the directions for future lncRNA-oriented research, which may ultimately result in patient-oriented therapeutic strategies for ASCVD.",
publisher = "MDPI",
journal = "Cells",
title = "LncRNAs as Regulators of Atherosclerotic Plaque Stability",
volume = "12",
number = "14",
doi = "10.3390/cells12141832"
}

Petković, A., Erceg, S., Munjas, J., Ninić, A., Vladimirov, S., Davidović, A., Vukmirović, L., Milanov, M., Cvijanović, D., Mitić, T.,& Sopić, M.. (2023). LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells
MDPI., 12(14).
https://doi.org/10.3390/cells12141832

Petković A, Erceg S, Munjas J, Ninić A, Vladimirov S, Davidović A, Vukmirović L, Milanov M, Cvijanović D, Mitić T, Sopić M. LncRNAs as Regulators of Atherosclerotic Plaque Stability. in Cells. 2023;12(14).
doi:10.3390/cells12141832 .

Petković, Aleksa, Erceg, Sanja, Munjas, Jelena, Ninić, Ana, Vladimirov, Sandra, Davidović, Aleksandar, Vukmirović, Luka, Milanov, Marko, Cvijanović, Dane, Mitić, Tijana, Sopić, Miron, "LncRNAs as Regulators of Atherosclerotic Plaque Stability" in Cells, 12, no. 14 (2023),
https://doi.org/10.3390/cells12141832 . .

TY  - CONF
AU  - Drndarević, Aneta
AU  - Draganov, Ivana
AU  - Miljković, Branislava
AU  - Davidović, Aleksandar
AU  - Cvijanović, Dane
AU  - Savković, Tatjana
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4506
AB  - Clinically significant drug-drug interactions (DDIs) are expected in patients with
cardiovascular diseases due to the number of drugs in therapy. The aim of the research was
to analyze DDIs during treatment which preceeded the admission to the cardiology
department. In the cardiology department of the Clinical Hospital Center Zvezdara, the
treatment of patients with ≥2 drugs before admission was analyzed. DDIs were identified
using the Lexicomp database (Lexi-Interact). Data were analyzed descriptively and with
linear regression analysis. During research, out of 132 participants 88.6% had ≥1, while
41.7% had ≥5 DDIs. The total number of DDIs was 648 (median 3, range 0-19). Men
constituted 64.4% of the population, with a median age of 70 years (32-90). Patients had 4
diagnoses (1-13) and 6 medications on admission (2-15). In 3.8% of patients,
contraindicated DDIs of anticholinergics were observed, 23.5% had DDIs that required
caution or a change in therapy, while interactions requiring follow-up were observed in
86.4% of patients. Angiotensin-converting enzyme inhibitors (30.4%), acetylsalicylic acid
(26.6%) and loop diuretics (16.5%) were most frequently involved in DDIs, while the most
common adverse events could be renal failure (21.5%), hypotension 19.7%) and bleeding
(13.7%). The number of drugs in therapy was a predictor of DDIs (p <0.001). Patients with
cardiovascular disease are often exposed to polypharmacy and consequently DDIs.
Cardiovascular drugs were most frequently involved in DDIs, but contraindicated DDIs were
present in anticholinergic drugs. In patients with cardiovascular diseases, monitoring of
renal function, hypotension and bleeding is required.
AB  - Klinički značajne interakcije (KZI) očekuju se kod pacijenata sa kardiovaskularnim
bolestima usled većeg broja lekova u terapiji. Cilj istraživanja je bio da se identifikuju i
analiziraju KZI pacijenata koje su prethodile prijemu na odeljenje kardiologije. U Kliničko-
bolničkom centru Zvezdara, na odeljenju kardiologije, analizirana je terapija pacijenata sa ≥2
leka pre prijema. KZI su identifikovane upotrebom baze Lexicomp (Lexi-Interact). Podaci su
analizirani deskriptivno i primenom linearne regresione analize. Od 132 učesnika u
istraživanju 88,6% je imalo ≥1, dok je 41,7% imalo ≥5 KZI. Ukupan broj KZI bio je 648
(medijana 3, opseg 0-19). U populaciji je bilo 64,4% muškaraca medijane starosti 70 godina
(32-90). Pacijenti su imali 4 dijagnoze (1-13) i 6 lekova na prijemu (2-15). Kod 3,8%
pacijenata utvrđene su KZI antiholinergika koje se smatraju kontraindikovanim. Približno
jedna četvrtina pacijenata (23,5%) je imala KZI koja zahteva oprez ili izmenu u terapiji dok
su kod 86,4% pacijenata uočene interakcije koje zahtevaju praćenje ishoda. Najčešće su u KZI
stupali inhibitori angiotenzin-konvertujućeg enzima (30,4%), acetilsalicilna kiselina (26,6%)
i diuretici petlje (16,5%) dok su najčešći neželjeni ishodi mogli biti bubrežna insuficijencija
(21,5%), hipotenzija (19,7%) i krvarenje (13,7%). Broj lekova u terapiji bio je prediktor za
KZI (p<0,001). Pacijenti sa kardiovaskularnim bolestima su često izloženi polifarmaciji i
posledično većem broju KZI. U KZI su najčešće stupali lekovi u terapiji kardiovaskularnih
bolesti ali su kontraindikovane KZI bile zastupljene kod antiholinergičkih lekova. Kod
pacijenata sa kardiovaskularnim bolestima potrebno je praćenje renalne funkcije,
hipotenzije i krvarenja.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission
T1  - Pregled klinički značajnih interakcija u terapiji kardiovaskularnih bolesti kod pacijenata na prijemu u bolnicu
VL  - 72
IS  - 4 suplement
SP  - S223
EP  - S224
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4506
ER  - 

@conference{
author = "Drndarević, Aneta and Draganov, Ivana and Miljković, Branislava and Davidović, Aleksandar and Cvijanović, Dane and Savković, Tatjana and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "Clinically significant drug-drug interactions (DDIs) are expected in patients with
cardiovascular diseases due to the number of drugs in therapy. The aim of the research was
to analyze DDIs during treatment which preceeded the admission to the cardiology
department. In the cardiology department of the Clinical Hospital Center Zvezdara, the
treatment of patients with ≥2 drugs before admission was analyzed. DDIs were identified
using the Lexicomp database (Lexi-Interact). Data were analyzed descriptively and with
linear regression analysis. During research, out of 132 participants 88.6% had ≥1, while
41.7% had ≥5 DDIs. The total number of DDIs was 648 (median 3, range 0-19). Men
constituted 64.4% of the population, with a median age of 70 years (32-90). Patients had 4
diagnoses (1-13) and 6 medications on admission (2-15). In 3.8% of patients,
contraindicated DDIs of anticholinergics were observed, 23.5% had DDIs that required
caution or a change in therapy, while interactions requiring follow-up were observed in
86.4% of patients. Angiotensin-converting enzyme inhibitors (30.4%), acetylsalicylic acid
(26.6%) and loop diuretics (16.5%) were most frequently involved in DDIs, while the most
common adverse events could be renal failure (21.5%), hypotension 19.7%) and bleeding
(13.7%). The number of drugs in therapy was a predictor of DDIs (p <0.001). Patients with
cardiovascular disease are often exposed to polypharmacy and consequently DDIs.
Cardiovascular drugs were most frequently involved in DDIs, but contraindicated DDIs were
present in anticholinergic drugs. In patients with cardiovascular diseases, monitoring of
renal function, hypotension and bleeding is required., Klinički značajne interakcije (KZI) očekuju se kod pacijenata sa kardiovaskularnim
bolestima usled većeg broja lekova u terapiji. Cilj istraživanja je bio da se identifikuju i
analiziraju KZI pacijenata koje su prethodile prijemu na odeljenje kardiologije. U Kliničko-
bolničkom centru Zvezdara, na odeljenju kardiologije, analizirana je terapija pacijenata sa ≥2
leka pre prijema. KZI su identifikovane upotrebom baze Lexicomp (Lexi-Interact). Podaci su
analizirani deskriptivno i primenom linearne regresione analize. Od 132 učesnika u
istraživanju 88,6% je imalo ≥1, dok je 41,7% imalo ≥5 KZI. Ukupan broj KZI bio je 648
(medijana 3, opseg 0-19). U populaciji je bilo 64,4% muškaraca medijane starosti 70 godina
(32-90). Pacijenti su imali 4 dijagnoze (1-13) i 6 lekova na prijemu (2-15). Kod 3,8%
pacijenata utvrđene su KZI antiholinergika koje se smatraju kontraindikovanim. Približno
jedna četvrtina pacijenata (23,5%) je imala KZI koja zahteva oprez ili izmenu u terapiji dok
su kod 86,4% pacijenata uočene interakcije koje zahtevaju praćenje ishoda. Najčešće su u KZI
stupali inhibitori angiotenzin-konvertujućeg enzima (30,4%), acetilsalicilna kiselina (26,6%)
i diuretici petlje (16,5%) dok su najčešći neželjeni ishodi mogli biti bubrežna insuficijencija
(21,5%), hipotenzija (19,7%) i krvarenje (13,7%). Broj lekova u terapiji bio je prediktor za
KZI (p<0,001). Pacijenti sa kardiovaskularnim bolestima su često izloženi polifarmaciji i
posledično većem broju KZI. U KZI su najčešće stupali lekovi u terapiji kardiovaskularnih
bolesti ali su kontraindikovane KZI bile zastupljene kod antiholinergičkih lekova. Kod
pacijenata sa kardiovaskularnim bolestima potrebno je praćenje renalne funkcije,
hipotenzije i krvarenja.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission, Pregled klinički značajnih interakcija u terapiji kardiovaskularnih bolesti kod pacijenata na prijemu u bolnicu",
volume = "72",
number = "4 suplement",
pages = "S223-S224",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4506"
}

Drndarević, A., Draganov, I., Miljković, B., Davidović, A., Cvijanović, D., Savković, T.,& Vezmar-Kovačević, S.. (2022). Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S223-S224.
https://hdl.handle.net/21.15107/rcub_farfar_4506

Drndarević A, Draganov I, Miljković B, Davidović A, Cvijanović D, Savković T, Vezmar-Kovačević S. Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission. in Arhiv za farmaciju. 2022;72(4 suplement):S223-S224.
https://hdl.handle.net/21.15107/rcub_farfar_4506 .

Drndarević, Aneta, Draganov, Ivana, Miljković, Branislava, Davidović, Aleksandar, Cvijanović, Dane, Savković, Tatjana, Vezmar-Kovačević, Sandra, "Clinically significant drug-drug interactions in the treatment of cardiovascular diseases on hospital admission" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S223-S224,
https://hdl.handle.net/21.15107/rcub_farfar_4506 .

TY  - CONF
AU  - Draganov, Ivana
AU  - Drndarević, Aneta
AU  - Miljković, Branislava
AU  - Davidović, Aleksandar
AU  - Cvijanović, Dane
AU  - Savković, Tatjana
AU  - Vezmar-Kovačević, Sandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4501
AB  - In patients with cardiovascular diseases drug-related problems (DRPs) can be
associated with hospitalization or rehospitalization. The aim of the research was to analyse
DRPs in the cardiology department on admission to the hospital. All patient records on
admission to the cardiology department of the Clinical Hospital Center Zvezdara during
2018., were analyzed. Demographic and treatment data of the patient before admission to
the hospital were collected. DRPs associated with pre-hospital treatment were identified and
classified according to the PCNE (Pharmaceutical Care Network Europe, version 9.1)
classification. DRPs were also evaluated as cause of the patient's hospitalization. Data were
analyzed descriptively and with linear regression analysis. During the research period, 143
patients were admitted to the cardiology department, with an average age of 69.75 ± 10.11
years, of which 65.7% were male. Patients had an average of 4.36±2.13 diagnoses and
5.24±3.39 medications on admission. We observed 1.85±1.37 DRPs per patient (range 0-5).
The most common DRP (75.6%) was lack of ≥1 drugs in the therapy preceding the
admission, most often statins (30.1% of patients), beta-blockers (25.9%), angiotensin-
converting enzyme inhibitors (17.5%) and antiarrhythmics/anticoagulants (12.6%). In 96
patients (67.1%) the identified DRPs could be associated with the cause of hospitalization.
Atrial fibrillation was the predictor of the number of DRPs in patients (p <0.001). In most
cardiovascular patients, the cause of hospitalization could be associated with DRPs before
admission. Incomplete therapy of the patient was commonly observed, the cause of which
may be inadequate prescribing or lack of adherence of the patient.
AB  - Pacijenti sa kardiovaskularnim bolestima susreću se sa brojnim problemima u terapiji
od kojih pojedini mogu biti uzrok hospitalizacije ili rehospitalizacije. Cilj istraživanja je bio da
se prikaže analiza terapijskih problema pacijenata na odeljenju kardiologije, prilikom
prijema u bolnicu. Analizirani su kartoni svih pacijenata primljenih na odeljenje kardiologije,
Kliničko-bolničkog centra Zvezdara tokom 2018. godine. Prikupljeni su demografski i podaci
o celokupnoj terapiji pacijenta pre prijema u bolnicu. Identifikovani su problemi u vezi sa
terapijom pre prijema u bolnicu i klasifikovani su prema PCNE (Pharmaceutical Care
Network Europe, verzija 9.1) klasifikaciji. Takođe, procenjeno je da li problemi u vezi sa
terapijom mogu biti uzrok hospitalizacije pacijenta. Podaci su analizirani deskriptivno i
primenom linearne regresione analize. U periodu istraživanja 143 pacijenta je primljeno na
odeljenje kardiologije, prosečne starosti 69,75±10,11 godina, od kojih je 65,7% bilo muškog
pola. Pacijenti su u proseku imali 4,36±2,13 dijagnoze i 5,24±3,39 lekova na prijemu.
Utvrđeno je prisustvo 1,85±1,37 terapijskih problema po pacijentu (opseg 0-5). Najčešći
terapijski problem (75,6%) bio je nedostatak ≥1 leka u terapiji i to najčešće statina (30,1%
pacijenata), beta-blokatora (25,9%), inhibitora angiotenzin-konvertujućeg enzima (17,5%) i
antiaritmika/anitkoagulanasa (12,6%). Kod 96 pacijenata (67,1%) su identifikovani
terapijski problemi dovedeni u vezu sa uzrokom hospitalizacije. Prediktivni faktor za broj
terapijskih problema kod pacijenata je bilo prisustvo atrijalne fibrilacije u anamnezi
(p<0,001). Uzrok hospitalizacije pacijenata sa kardiovaskularnim bolestima se često može
povezati sa problemima u terapiji pre prijema. Najčešće se uočava nepotpuna terapija
pacijenta čiji uzrok može biti neodgovarajuće propisivanje ili nedostatak adherence
pacijenta.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Drug-related problems of patients with cardiovascular diseases on hospital admission
T1  - Terapijski problemi pacijenata sa kardiovaskularnim bolestima na prijemu u bolnicu
VL  - 72
IS  - 4 suplement
SP  - S221
EP  - S222
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4501
ER  - 

@conference{
author = "Draganov, Ivana and Drndarević, Aneta and Miljković, Branislava and Davidović, Aleksandar and Cvijanović, Dane and Savković, Tatjana and Vezmar-Kovačević, Sandra",
year = "2022",
abstract = "In patients with cardiovascular diseases drug-related problems (DRPs) can be
associated with hospitalization or rehospitalization. The aim of the research was to analyse
DRPs in the cardiology department on admission to the hospital. All patient records on
admission to the cardiology department of the Clinical Hospital Center Zvezdara during
2018., were analyzed. Demographic and treatment data of the patient before admission to
the hospital were collected. DRPs associated with pre-hospital treatment were identified and
classified according to the PCNE (Pharmaceutical Care Network Europe, version 9.1)
classification. DRPs were also evaluated as cause of the patient's hospitalization. Data were
analyzed descriptively and with linear regression analysis. During the research period, 143
patients were admitted to the cardiology department, with an average age of 69.75 ± 10.11
years, of which 65.7% were male. Patients had an average of 4.36±2.13 diagnoses and
5.24±3.39 medications on admission. We observed 1.85±1.37 DRPs per patient (range 0-5).
The most common DRP (75.6%) was lack of ≥1 drugs in the therapy preceding the
admission, most often statins (30.1% of patients), beta-blockers (25.9%), angiotensin-
converting enzyme inhibitors (17.5%) and antiarrhythmics/anticoagulants (12.6%). In 96
patients (67.1%) the identified DRPs could be associated with the cause of hospitalization.
Atrial fibrillation was the predictor of the number of DRPs in patients (p <0.001). In most
cardiovascular patients, the cause of hospitalization could be associated with DRPs before
admission. Incomplete therapy of the patient was commonly observed, the cause of which
may be inadequate prescribing or lack of adherence of the patient., Pacijenti sa kardiovaskularnim bolestima susreću se sa brojnim problemima u terapiji
od kojih pojedini mogu biti uzrok hospitalizacije ili rehospitalizacije. Cilj istraživanja je bio da
se prikaže analiza terapijskih problema pacijenata na odeljenju kardiologije, prilikom
prijema u bolnicu. Analizirani su kartoni svih pacijenata primljenih na odeljenje kardiologije,
Kliničko-bolničkog centra Zvezdara tokom 2018. godine. Prikupljeni su demografski i podaci
o celokupnoj terapiji pacijenta pre prijema u bolnicu. Identifikovani su problemi u vezi sa
terapijom pre prijema u bolnicu i klasifikovani su prema PCNE (Pharmaceutical Care
Network Europe, verzija 9.1) klasifikaciji. Takođe, procenjeno je da li problemi u vezi sa
terapijom mogu biti uzrok hospitalizacije pacijenta. Podaci su analizirani deskriptivno i
primenom linearne regresione analize. U periodu istraživanja 143 pacijenta je primljeno na
odeljenje kardiologije, prosečne starosti 69,75±10,11 godina, od kojih je 65,7% bilo muškog
pola. Pacijenti su u proseku imali 4,36±2,13 dijagnoze i 5,24±3,39 lekova na prijemu.
Utvrđeno je prisustvo 1,85±1,37 terapijskih problema po pacijentu (opseg 0-5). Najčešći
terapijski problem (75,6%) bio je nedostatak ≥1 leka u terapiji i to najčešće statina (30,1%
pacijenata), beta-blokatora (25,9%), inhibitora angiotenzin-konvertujućeg enzima (17,5%) i
antiaritmika/anitkoagulanasa (12,6%). Kod 96 pacijenata (67,1%) su identifikovani
terapijski problemi dovedeni u vezu sa uzrokom hospitalizacije. Prediktivni faktor za broj
terapijskih problema kod pacijenata je bilo prisustvo atrijalne fibrilacije u anamnezi
(p<0,001). Uzrok hospitalizacije pacijenata sa kardiovaskularnim bolestima se često može
povezati sa problemima u terapiji pre prijema. Najčešće se uočava nepotpuna terapija
pacijenta čiji uzrok može biti neodgovarajuće propisivanje ili nedostatak adherence
pacijenta.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Drug-related problems of patients with cardiovascular diseases on hospital admission, Terapijski problemi pacijenata sa kardiovaskularnim bolestima na prijemu u bolnicu",
volume = "72",
number = "4 suplement",
pages = "S221-S222",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4501"
}

Draganov, I., Drndarević, A., Miljković, B., Davidović, A., Cvijanović, D., Savković, T.,& Vezmar-Kovačević, S.. (2022). Drug-related problems of patients with cardiovascular diseases on hospital admission. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S221-S222.
https://hdl.handle.net/21.15107/rcub_farfar_4501

Draganov I, Drndarević A, Miljković B, Davidović A, Cvijanović D, Savković T, Vezmar-Kovačević S. Drug-related problems of patients with cardiovascular diseases on hospital admission. in Arhiv za farmaciju. 2022;72(4 suplement):S221-S222.
https://hdl.handle.net/21.15107/rcub_farfar_4501 .

Draganov, Ivana, Drndarević, Aneta, Miljković, Branislava, Davidović, Aleksandar, Cvijanović, Dane, Savković, Tatjana, Vezmar-Kovačević, Sandra, "Drug-related problems of patients with cardiovascular diseases on hospital admission" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S221-S222,
https://hdl.handle.net/21.15107/rcub_farfar_4501 .